GSK vs. WST: GSK vs. West Pharmaceutical Services Stock Comparison

Company Profile

GSK (GSK) and West Pharmaceutical Services (WST) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GSK is classified in Pharmaceuticals while WST is classified in Life Sciences Tools & Services.

West Pharmaceutical Services (WST) trades as ordinary local shares, while GSK (GSK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both GSK (GSK) at 28.27% and West Pharmaceutical Services (WST) at 21.23% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

West Pharmaceutical Services (WST) at 18.81% keeps the most of each sales dollar — above its industry’s net margin range — and GSK (GSK) at 12.97% also retains a top-quartile share.

Both GSK (GSK) at 32.14% and West Pharmaceutical Services (WST) at 25.37% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both GSK (GSK) at 4.11% and West Pharmaceutical Services (WST) at 6.25% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

GSK (GSK) at 123.15% sits in the top EPS growth quartile, while West Pharmaceutical Services (WST) at 1.49% is closer to the peer norm — faster per-share earnings growth for GSK.

Growth Metrics

Financial Strength

West Pharmaceutical Services (WST) at 2.82 keeps current ratio within its industry’s typical mid-range, while GSK (GSK) at 0.86 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GSK.

West Pharmaceutical Services (WST) at 0.11 carries an industry-typical debt-to-equity mix, while GSK (GSK) at 1.30 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Both GSK (GSK) at 1.57% and West Pharmaceutical Services (WST) at 0.22% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both GSK (GSK) at 63.33% and West Pharmaceutical Services (WST) at 9.88% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

GSK (GSK) at 17.54 is near its industry’s usual P/E ratio, while West Pharmaceutical Services (WST) at 44.87 sits in the richer quartile — WST needs stronger growth or earnings quality to justify the premium.

GSK (GSK) at 3.01 sits in the cheaper P/S ratio quartile while West Pharmaceutical Services (WST) at 8.20 prices around its industry’s middle — GSK costs less per dollar of sales, though read it alongside growth and margins.

GSK (GSK) at 4.02 is valued about in line with its industry on P/B ratio, while West Pharmaceutical Services (WST) at 9.40 carries an above-peer premium to book — WST is pricier on assets.

Valuation Metrics